Dasatinib, sold under the brand name Sprycel, is a BCR-ABL tyrosine kinase inhibitor often utilized in the treatment of chronic myeloid leukemia (CML) [1]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.